Nuformix plc
Market Cap
$3.59M
P/E Ratio
—
EPS
—
Dividend Yield
0.00%
52-Week Range
$0.07 — $0.56
Volume
4.40M
Avg Volume
39.60M
Beta
1.54
Get alerted when NFX.L hits your target price.
Free — enter your email to get started
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.06
P/S (TTM)
0.00
P/B (TTM)
4.85
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-0.84%
ROA (TTM)
-0.64%
ROIC
—
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
—
Debt/Equity
0.00
Current Ratio
0.52
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
-1.25%
EPS Growth (5Y)
-0.72%
Sales Growth (3Y)
+0.00%
Sales Growth (5Y)
-0.15%
EPS Est (This Year)
$-0.00
EPS Est (Next Year)
$-0.00
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$0.00
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
2.11B
Float
1.89B
Free Float %
89.68%
Sector
Healthcare
Industry
Biotechnology
Country
GB
Exchange
LSE
IPO Date
2015-12-17
Employees
3
CEO
Daniel John Gooding
Index Membership
—
Website
https://www.nuformix.com
Nuformix plc (NFX.L) is a healthcare company in the biotechnology industry listed on the LSE. With a market capitalization of $3.59M, NFX.L is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare NFX.L against other stocks using dozens of fundamental and technical filters.
No, Nuformix plc (NFX.L) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Nuformix plc (NFX.L) has a market capitalization of $3.59 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.